Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

64.03 +1.58 (+2.54%)
Streaming Delayed Price Updated: 10:48 AM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 649,088
Open 62.78
Bid (Size) 64.00 (2)
Ask (Size) 64.09 (18)
Prev. Close 62.45
Today's Range 62.47 - 64.20
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued... 
Via Benzinga

Performance

YTD
+250.30%
+250.30%
1 Month
+17.17%
+17.17%
3 Month
+9.22%
+9.22%
6 Month
-9.64%
-9.64%
1 Year
+486.94%
+486.94%

More News

Read More
Viking Therapeutics Unusual Options Activity
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Viking Therapeutics Unusual Options Activity For September 24
Via Benzinga
What the Options Market Tells Us About Viking Therapeutics
Via Benzinga
Why Viking Therapeutics Stock Topped the Market Today
Via The Motley Fool
Is Viking Therapeutics Stock a Buy?
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
Is Viking Therapeutics Ready For Another Surge?
Via MarketBeat
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
Via Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Via The Motley Fool
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Via MarketBeat
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Via The Motley Fool
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
These 2 Biotech Stocks Are Set to Soar
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.